Research programme: RNA modifying enzymes inhibitors - Storm Therapeutics
Latest Information Update: 09 May 2022
At a glance
- Originator Storm Therapeutics
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action ADAR protein inhibitors; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Coronavirus infections
Most Recent Events
- 03 May 2022 Early research in Coronavirus infections in United Kingdom (unspecified route), prior to May 2022
- 14 Oct 2021 Double-stranded RNA-specific adenosine deaminase (ADAR) inhibitors programme licensed to Exelixis worldwide
- 14 Oct 2021 Early research in Cancer in United Kingdom (unspecified route) before October 2021